No, Compass Therapeutics and Compass Pathways operate as clinical-stage biopharmaceutical enterprises that currently generate little to no commercial product revenue. They report ongoing net losses as they dedicate heavy capital resources to laboratory research, drug discovery, and multi-phase human clinical trials.